University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Bruce Cree, Ph.D., M.D.


Dr. Bruce Cree is a neurologist with a special interest in multiple sclerosis. In addition to providing patient care, Cree focuses on the development of novel therapies through clinical trials. Cree received his medical degree and doctorate in biochemistry from the University of California, San Francisco. He went on to complete his neurology residency at Columbia University. Cree is the recipient of a National Institute of Health post-doctoral grant for multiple sclerosis clinical research and is a Sylvia Lawry fellow of the National Multiple Sclerosis Society.


Multiple Sclerosis Center
1500 Owens St., Suite 320
San Francisco, CA 94158
Phone: (415) 353-2069
Fax: (415) 353-2633

Hours: Monday to Friday
8:30 a.m. – 4:30 p.m.

Conditions & Treatments

More about Bruce Cree


UCSF School of Medicine 1997


Columbia Presbyterian Medical Center, Neurology 2001


UCSF Medical Center, Neurology 2003

Selected Research and Publications

  1. Orengo JP, Pekmezci M, Cree BA. Simultaneous serum aquaporin-4 antibody and CSF NMDA receptor antibody-positive encephalitis. Neurol Neuroimmunol Neuroinflamm. 2015 Jun; 2(3):e101.
  2. Isobe N, Madireddy L, Khankhanian P, Matsushita T, Caillier SJ, Moré JM, Gourraud PA, McCauley JL, Beecham AH. An ImmunoChip study of multiple sclerosis risk in African Americans. Brain. 2015 Jun; 138(Pt 6):1518-30.
  3. Spencer CM, Crabtree-Hartman EC, Lehmann-Horn K, Cree BA, Zamvil SS. Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm. 2015 Jun; 2(3):e76.
  4. Gelfand JM, Genrich G, Green AJ, Tihan T, Cree BA. Encephalitis of unclear origin diagnosed by brain biopsy : a diagnostic challenge. JAMA Neurol. 2015 Jan 1; 72(1):66-72.
  5. Cree BA. Demyelinating disease: Is TOPIC the last trial for clinically isolated syndrome? Nat Rev Neurol. 2015 Jan; 11(1):6-7.
  6. Calkwood J, Cree B, Crayton H, Kantor D, Steingo B, Barbato L, Hashmonay R, Agashivala N, McCague K, Tenenbaum N, Edwards K. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurol. 2014; 14(1):220.
  7. Kappos L, Bar-Or A, Cree B, Fox R, Giovannoni G, Gold R, Vermersch P, Lam E, Pohlmann H, Wallström E. Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis: Design of the phase 3 EXPAND trial. Mult Scler Relat Disord. 2014 Nov; 3(6):752.
  8. Cree B, Chin P, Ritter S, Meier DP, Rosenstiel PV, Casiano S, Kappos L. Four-year Expanded Disability Status Scale (EDSS) outcomes in patients treated with fingolimod in the Phase 3 and extension trial program. Mult Scler Relat Disord. 2014 Nov; 3(6):751-2.
  9. Kaufman M, Cree BA, De Sèze J, Fox RJ, Gold R, Hartung HP, Jeffery D, Kappos L, Montalbán X, Weinstock-Guttman B, Ticho B, Duda P, Pace A, Campagnolo D. Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. J Neurol. 2015 Feb; 262(2):326-36.
  10. Cree B. Mycophenolate mofetil to treat neuromyelitis optica: is it time for a randomized trial? JAMA Neurol. 2014 Nov 1; 71(11):1354-7.
  11. Gourraud PA, Henry RG, Cree BA, Crane JC, Lizee A, Olson MP, Santaniello AV, Datta E, Zhu AH, Bevan CJ, Gelfand JM, Graves JS, Goodin DS, Green AJ, von Büdingen HC, Waubant E, Zamvil SS, Crabtree-Hartman E, Nelson S, Baranzini SE, Hauser SL. Precision medicine in chronic disease management: The multiple sclerosis BioScreen. Ann Neurol. 2014 Nov; 76(5):633-42.
  12. Gelfand JM, Cotter J, Klingman J, Huang EJ, Cree BA. Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO. Neurol Neuroimmunol Neuroinflamm. 2014 Oct; 1(3):e34.
  13. Malik R, Lewis A, Cree BA, Ratelade J, Rossi A, Verkman AS, Bollen AW, Ralph JW. Transient hyperckemia in the setting of neuromyelitis optica (NMO). Muscle Nerve. 2014 Nov; 50(5):859-62.
  14. Schlaeger R, Papinutto N, Panara V, Bevan C, Lobach IV, Bucci M, Caverzasi E, Gelfand JM, Green AJ, Jordan KM, Stern WA, von Büdingen HC, Waubant E, Zhu AH, Goodin DS, Cree BA, Hauser SL, Henry RG. Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol. 2014 Oct; 76(4):568-80.
  15. Varrin-Doyer M, Shetty A, Spencer CM, Schulze-Topphoff U, Weber MS, Bernard CC, Forsthuber T, Cree BA, Slavin AJ, Zamvil SS. MOG transmembrane and cytoplasmic domains contain highly stimulatory T-cell epitopes in MS. Neurol Neuroimmunol Neuroinflamm. 2014 Aug; 1(2):e20.
  16. Azevedo CJ, Kornak J, Chu P, Sampat M, Okuda DT, Cree BA, Nelson SJ, Hauser SL, Pelletier D. In vivo evidence of glutamate toxicity in multiple sclerosis. Ann Neurol. 2014 Aug; 76(2):269-78.
  17. Llufriu S, Kornak J, Ratiney H, Oh J, Brenneman D, Cree BA, Sampat M, Hauser SL, Nelson SJ, Pelletier D. Magnetic resonance spectroscopy markers of disease progression in multiple sclerosis. JAMA Neurol. 2014 Jul 1; 71(7):840-7.
  18. Cree BA. 2014 multiple sclerosis therapeutic update. Neurohospitalist. 2014 Apr; 4(2):63-5.
  19. Fox RJ, Cree BA, De Sèze J, Gold R, Hartung HP, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Duda P. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology. 2014 Apr 29; 82(17):1491-8.
  20. Bevan CJ, Cree BA. Disease activity free status: a new end point for a new era in multiple sclerosis clinical research? JAMA Neurol. 2014 Mar; 71(3):269-70.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.